Sovaldi sofosbuvir: Interim Phase II data

Interim data from 28 evaluable patients with chronic HCV genotype 1 or 4 infection and decompensated liver disease in the open-label, U.S. Phase II IMPACT trial showed that a once-daily oral regimen of 150 mg Olysio simeprevir, 400 mg Sovaldi sofosbuvir and 60 mg Daklinza daclatasvir for 12 weeks led to an SVR 4 weeks after the end of treatment in 100% of patients. Data were presented at the European Association for the Study of the Liver meeting in Vienna. SVR12 data will be reported later this year. ...